XIX International AIDS Conference. Interview with Adeeba Kamarulzaman from the University of Malaya in Kuala Lumpur, Malaysia. She talks about the obstacles and possibilities of ending HIV and AIDS.

Dr Anthony Fauci from the National Institutes of Health (NIH) gives his thoughts on the future of the AIDS epidemic. He also talks about the targets of the current and future HIV/AIDS research and about international partnerships in the AIDS response.

XVII International AIDS Conference in Mexico City. Jeffrey Sturchio, Vice President of Merck & Co, talks about the development of protease inhibitors in 1996 and the relationship between the activists and the drug industry.

XVII International AIDS Conference in Mexico City. Jeffrey Sturchio, Vice President of Merck & Co, talks about the development of protease inhibitors in 1996 and the relationship between the activists and the drug industry.

XVII International AIDS Conference in Mexico City. American HIV/AIDS pioneer Dr Anthony Fauci from the National Institute of Allergy and Infectious Diseases (NIAID) talks about the disappointments of the latest HIV vaccine trials, and the leadership of Peter Piot.

XVII International AIDS Conference in Mexico City. American HIV/AIDS pioneer Dr Anthony Fauci from the National Institute of Allergy and Infectious Diseases (NIAID) talks about the disappointments of the latest HIV vaccine trials, and the leadership of Peter Piot.

XVII International AIDS Confrerence in Mexico City. The UNAIDS Executive Director, Peter Piot, is leading the seminar "Taking the Long-Term View AIDS 2031". He talks about the future leadership and international collaboration in HIV and AIDS research.

XVII International AIDS Conference in Mexico City. Dr Daria Hazuda from MSD, who has been involved in antiretroviral drug development during the past 20 years, holds a presentation. She is also interviewed about leadership and the progress of ARV and vaccine development.

Daria Hazuda from MSD explains the virology of HIV and talks about the past clinical studies on ARV, in particular integrase inhibitors, which she has been involved in. She also reflects on HIV as an exceptional virus and how to influence a new generation of HIV researchers.